{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:49:20Z","timestamp":1792597760848,"version":"4.5.0"},"reference-count":98,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Diabetic kidney disease (DKD) is the most prevalent form of chronic kidney disease and kidney failure globally. In the last decade, RAAS inhibitors, SGLT2 inhibitors, GLP-1-receptor agonists, and non-steroidal mineralocorticoid receptor antagonists have made significant advancements. However, despite the use of these drugs, patients with DKD often show a residual renal risk. In this narrative review, we synthesize current evidence on residual renal risk in DKD, focusing on underlying mechanisms, high-risk clinical phenotypes, and therapeutic gaps. Methods: A narrative review of current literature available in clinical trials, post hoc analysis studies, observational studies, and research into mechanisms of action or processes related to DKD was performed. Results: The central element of residual renal risk in DKD is persistent inflammation, fibrosis, tubulointerstitial injury\/injury to both renal and vascular systems, and metabolic memory. These represent the four types of renal-related problems that have been identified. Non-albuminuric DKD, rapid progressors, late presenters with multiple comorbidities, tend to exhibit an extreme burden associated with some of these entities. Conclusions: The remaining risk factors that cannot be adequately addressed by current medical treatments represent major opportunities for improved clinical management, i.e., those at high-risk of kidney failure. Future research initiatives are required to further refine and improve therapeutic approaches for early intervention in patients with DKD. In addition, development of specific treatments targeting inflammation, fibrosis and metabolism in the kidney will lead to better therapeutic results and decreased risk of progressive loss of kidney function.<\/jats:p>","DOI":"10.3390\/jcm15030921","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T09:21:40Z","timestamp":1769505700000},"page":"921","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Residual Renal Risk in Diabetic Nephropathy Despite Contemporary Therapies"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9421-3546","authenticated-orcid":false,"given":"Reinhart","family":"Speeckaert","sequence":"first","affiliation":[{"name":"Department of Dermatology, Ghent University Hospital, 9000 Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Delrue","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Ghent University Hospital, 9000 Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9183-4390","authenticated-orcid":false,"given":"Marijn M.","family":"Speeckaert","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Ghent University Hospital, 9000 Ghent, Belgium"},{"name":"Research Foundation-Flanders (FWO), 1000 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic Kidney Disease: Challenges, Progress, and Possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"15018","DOI":"10.1038\/nrdp.2015.18","article-title":"Diabetic Kidney Disease","volume":"1","author":"Thomas","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney Disease and Increased Mortality Risk in Type 2 Diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, Regional, and National Burden of Chronic Kidney Disease, 1990\u20132017: A Systematic Analysis for the Global Burden of Disease Study 2017","volume":"395","author":"Bikbov","year":"2020","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and Regional Diabetes Prevalence Estimates for 2019 and Projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th Edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"The EMPA-KIDNEY Collaborative Group (2023). Empagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med., 388, 117\u2013127.","DOI":"10.1056\/NEJMoa2204233"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 Receptor Agonists on Kidney and Cardiovascular Disease Outcomes: A Meta-Analysis of Randomised Controlled Trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/dom.13417","article-title":"New Clinical Trial Designs for Establishing Drug Efficacy and Safety in a Precision Medicine Era","volume":"20","author":"Heerspink","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.kint.2016.08.025","article-title":"Progression of Chronic Kidney Disease: Too Much Cellular Talk Causes Damage","volume":"91","author":"Gewin","year":"2017","journal-title":"Kidney Int."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev-physiol-022516-034227","article-title":"Mechanisms of Renal Fibrosis","volume":"80","author":"Humphreys","year":"2018","journal-title":"Annu. Rev. Physiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1681\/ASN.2007091048","article-title":"The Role of Inflammatory Cytokines in Diabetic Nephropathy","volume":"19","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.semnephrol.2012.07.006","article-title":"Can Existing Drugs Approved for Other Indications Retard Renal Function Decline in Patients with Type 1 Diabetes and Nephropathy?","volume":"32","author":"Doria","year":"2012","journal-title":"Semin. Nephrol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S2213-8587(15)00094-7","article-title":"Non-Proteinuric Pathways in Loss of Renal Function in Patients with Type 2 Diabetes","volume":"3","author":"Porrini","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2215\/CJN.11511114","article-title":"Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View","volume":"10","author":"Gansevoort","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2337\/dc17-1011","article-title":"Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis","volume":"40","author":"Nadkarni","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1053\/j.ackd.2017.10.011","article-title":"The Global Epidemiology of Diabetes and Kidney Disease","volume":"25","author":"Koye","year":"2018","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.2337\/db05-1620","article-title":"Risk Factors for Renal Dysfunction in Type 2 Diabetes: U.K. Prospective Diabetes Study 74","volume":"55","author":"Retnakaran","year":"2006","journal-title":"Diabetes"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1464-5491.2010.02967.x","article-title":"\u2018Glycaemic Variability\u2019: A New Therapeutic Challenge in Diabetes and the Critical Care Setting","volume":"27","author":"Ceriello","year":"2010","journal-title":"Diabet. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cge.12121","article-title":"Epigenetic Changes in Diabetes","volume":"84","author":"Keating","year":"2013","journal-title":"Clin. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1681\/ASN.2012040390","article-title":"Mechanisms and Treatment of CKD","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1111\/j.1523-1755.2005.09911.x","article-title":"The Role of Renin-Angiotensin-Aldosterone System in the Progression of Chronic Kidney Disease","volume":"68","author":"Remuzzi","year":"2005","journal-title":"Kidney Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41591-025-04057-z","article-title":"A Meta-Analysis of Albuminuria as a Surrogate Endpoint for Kidney Failure","volume":"32","author":"Heerspink","year":"2026","journal-title":"Nat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S2213-8587(18)30313-9","article-title":"Change in Albuminuria and Subsequent Risk of End-Stage Kidney Disease: An Individual Participant-Level Consortium Meta-Analysis of Observational Studies","volume":"7","author":"Coresh","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Provenzano, M., Hu, L., Tringali, E., Senatore, M., Talarico, R., Di Dio, M., Ruotolo, C., La Manna, G., Garofalo, C., and Zaza, G. (2024). Improving Kidney Disease Care: One Giant Leap for Nephrology. Biomedicines, 12.","DOI":"10.3390\/biomedicines12040828"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00125-006-0215-6","article-title":"Anaemia in Diabetes: Is There a Rationale to TREAT?","volume":"49","author":"Thomas","year":"2006","journal-title":"Diabetologia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal Outcomes with Telmisartan, Ramipril, or Both, in People at High Vascular Risk (the ONTARGET Study): A Multicentre, Randomised, Double-Blind, Controlled Trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2215\/CJN.09340817","article-title":"Hyperkalemia Across the Continuum of Kidney Function","volume":"13","author":"Palmer","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_37","first-page":"S212","article-title":"Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin-Aldosterone System Inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am. J. Manag. Care"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The Incidence and Implications of Aldosterone Breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of Aldosterone to Cardiovascular and Renal Inflammation and Fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.2337\/dc14-1296","article-title":"Diabetic Kidney Disease: A Report from an ADA Consensus Conference","volume":"37","author":"Tuttle","year":"2014","journal-title":"Diabetes Care"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1053\/j.ackd.2017.12.002","article-title":"Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease","volume":"25","author":"Alicic","year":"2018","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/dom.12654","article-title":"Dapagliflozin Reduces Albuminuria in Patients with Diabetes and Hypertension Receiving Renin-angiotensin Blockers","volume":"18","author":"Heerspink","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients with Type 1 Diabetes Mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting Renal Glucose Reabsorption to Treat Hyperglycaemia: The Pleiotropic Effects of SGLT2 Inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.kint.2020.02.041","article-title":"The Role of Renal Hypoxia in the Pathogenesis of Diabetic Kidney Disease: A Promising Target for Newer Renoprotective Agents Including SGLT2 Inhibitors?","volume":"98","author":"Hesp","year":"2020","journal-title":"Kidney Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.12.027","article-title":"Renoprotective Effects of Sodium-Glucose Cotransporter-2 Inhibitors","volume":"94","author":"Heerspink","year":"2018","journal-title":"Kidney Int."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","article-title":"Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease","volume":"141","author":"Mazer","year":"2020","journal-title":"Circulation"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Provenzano, M., Minutolo, R., Chiodini, P., Bellizzi, V., Nappi, F., Russo, D., Borrelli, S., Garofalo, C., Iodice, C., and De Stefano, T. (2018). Competing-Risk Analysis of Death and End Stage Kidney Disease by Hyperkalaemia Status in Non-Dialysis Chronic Kidney Disease Patients Receiving Stable Nephrology Care. J. Clin. Med., 7.","DOI":"10.20944\/preprints201811.0170.v1"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.13969","article-title":"Pathophysiologic Mechanisms in Diabetic Kidney Disease: A Focus on Current and Future Therapeutic Targets","volume":"22","author":"Jaisser","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern with SGLT2 Inhibitors","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/ki.2011.379","article-title":"Chronic Kidney Disease after Acute Kidney Injury: A Systematic Review and Meta-Analysis","volume":"81","author":"Coca","year":"2012","journal-title":"Kidney Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND): A Double-Blind, Randomised Placebo-Controlled Trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, Mortality, and Kidney Outcomes with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Cardiovascular Outcome Trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrneph.2017.123","article-title":"GLP-1 and the Kidney: From Physiology to Pharmacology and Outcomes in Diabetes","volume":"13","author":"Muskiet","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.kisu.2017.10.005","article-title":"Novel Therapies for Diabetic Kidney Disease","volume":"8","author":"Cherney","year":"2018","journal-title":"Kidney Int. Suppl."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41581-020-00367-2","article-title":"Incretin Drugs in Diabetic Kidney Disease: Biological Mechanisms and Clinical Evidence","volume":"17","author":"Alicic","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.kint.2022.06.013","article-title":"Executive Summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: An Update Based on Rapidly Emerging New Evidence","volume":"102","author":"Rossing","year":"2022","journal-title":"Kidney Int."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease","volume":"102","author":"Rossing","year":"2022","journal-title":"Kidney Int."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"9641","DOI":"10.1038\/s41467-025-64640-3","article-title":"Finerenone versus Spironolactone in Patients with Chronic Kidney Disease and Type 2 Diabetes: A Target Trial Emulation","volume":"16","author":"Wang","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and Kidney Outcomes with Finerenone in Patients with Type 2 Diabetes and Chronic Kidney Disease: The FIDELITY Pooled Analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11892-018-0984-6","article-title":"Role of the Immune System in Diabetic Kidney Disease","volume":"18","author":"Hickey","year":"2018","journal-title":"Curr. Diabetes Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1042\/CS20120198","article-title":"Inflammation and the Pathogenesis of Diabetic Nephropathy","volume":"124","author":"Wada","year":"2013","journal-title":"Clin. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0272-6386(12)80312-X","article-title":"Tubulointerstitial Changes as a Major Determinant in the Progression of Renal Damage","volume":"20","author":"Nath","year":"1992","journal-title":"Am. J. Kidney Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1681\/ASN.2006070704","article-title":"Chronic Kidney Disease Progression","volume":"17","author":"Eddy","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1681\/ASN.2011060627","article-title":"Circulating TNF Receptors 1 and 2 Predict ESRD in Type 2 Diabetes","volume":"23","author":"Niewczas","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1681\/ASN.2013091002","article-title":"Improved Glycemic Control and Risk of ESRD in Patients with Type 1 Diabetes and Proteinuria","volume":"25","author":"Skupien","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/nrneph.2011.149","article-title":"Cellular and Molecular Mechanisms of Renal Fibrosis","volume":"7","author":"Liu","year":"2011","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/MNH.0b013e3283521cfa","article-title":"Renal Interstitial Fibrosis: Mechanisms and Evaluation","volume":"21","author":"Farris","year":"2012","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1172\/JCI72267","article-title":"Cellular and Molecular Mechanisms in Kidney Fibrosis","volume":"124","author":"Duffield","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"C216","DOI":"10.1152\/ajpcell.00328.2012","article-title":"Cellular Mechanisms of Tissue Fibrosis. 1. Common and Organ-Specific Mechanisms Associated with Tissue Fibrosis","volume":"304","author":"Zeisberg","year":"2013","journal-title":"Am. J. Physiol.-Cell Physiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1056\/NEJM199411103311907","article-title":"Transforming Growth Factor Beta in Tissue Fibrosis","volume":"331","author":"Border","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e3596","DOI":"10.1002\/dmrr.3596","article-title":"Role of Renal Tubular Programed Cell Death in Diabetic Kidney Disease","volume":"39","author":"Zhou","year":"2023","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00041552-200401000-00005","article-title":"Cellular Responses to Protein Overload: Key Event in Renal Disease Progression","volume":"13","author":"Zoja","year":"2004","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in Albuminuria as a Surrogate Endpoint for Progression of Kidney Disease: A Meta-Analysis of Treatment Effects in Randomised Clinical Trials","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0272-6386(00)70036-9","article-title":"Sonographic Evaluation of Renal Failure","volume":"35","year":"2000","journal-title":"Am. J. Kidney Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/ki.2008.350","article-title":"Chronic Hypoxia as a Mechanism of Progression of Chronic Kidney Diseases: From Hypothesis to Novel Therapeutics","volume":"74","author":"Fine","year":"2008","journal-title":"Kidney Int."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1161\/01.HYP.0000167121.14254.a0","article-title":"Kidney in Early Atherosclerosis","volume":"45","author":"Chade","year":"2005","journal-title":"Hypertension"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1681\/ASN.V133806","article-title":"Role of the Microvascular Endothelium in Progressive Renal Disease","volume":"13","author":"Kang","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1146\/annurev.pharmtox.48.113006.094615","article-title":"Biomarkers of Acute Kidney Injury","volume":"48","author":"Vaidya","year":"2008","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Diabetes Control and Complications Trial Research Group (1993). The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. N. Engl. J. Med., 329, 977\u2013986.","DOI":"10.1056\/NEJM199309303291401"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"The Epidemiology of Diabetes Interventions and Complications (EDIC) Study, and The Writing Team for the Diabetes Control and Complications Trial (2003). Sustained Effect of Intensive Treatment of Type 1 Diabetes Mellitus on Development and Progression of Diabetic Nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. JAMA, 290, 2159.","DOI":"10.1001\/jama.290.16.2159"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","article-title":"The Pathobiology of Diabetic Complications","volume":"54","author":"Brownlee","year":"2005","journal-title":"Diabetes"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/CIRCRESAHA.110.223545","article-title":"Oxidative Stress and Diabetic Complications","volume":"107","author":"Giacco","year":"2010","journal-title":"Circ. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/cvr\/cvr024","article-title":"Epigenetic Mechanisms in Diabetic Vascular Complications","volume":"90","author":"Reddy","year":"2011","journal-title":"Cardiovasc. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1152\/physrev.00045.2011","article-title":"Mechanisms of Diabetic Complications","volume":"93","author":"Forbes","year":"2013","journal-title":"Physiol. Rev."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1097\/HJH.0b013e3283495cd6","article-title":"Clinical Significance of Nonalbuminuric Renal Impairment in Type 2 Diabetes","volume":"29","author":"Penno","year":"2011","journal-title":"J. Hypertens."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s001250050694","article-title":"Predictors of the Progression of Diabetic Nephropathy and the Beneficial Effect of Angiotensin-Converting Enzyme Inhibitors in NIDDM Patients","volume":"40","author":"Yokoyama","year":"1997","journal-title":"Diabetologia"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.semnephrol.2007.01.012","article-title":"Histopathology of Diabetic Nephropathy","volume":"27","author":"Fioretto","year":"2007","journal-title":"Semin. Nephrol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000333249","article-title":"Renal Dysfunction in the Presence of Normoalbuminuria in Type 2 Diabetes: Results from the DEMAND Study","volume":"2","author":"Dwyer","year":"2012","journal-title":"Cardiorenal Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1001\/jama.2014.6634","article-title":"Decline in Estimated Glomerular Filtration Rate and Subsequent Risk of End-Stage Renal Disease and Mortality","volume":"311","author":"Coresh","year":"2014","journal-title":"JAMA"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/ki.2015.228","article-title":"Comorbidity as a Driver of Adverse Outcomes in People with Chronic Kidney Disease","volume":"88","author":"Tonelli","year":"2015","journal-title":"Kidney Int."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/3\/921\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T09:34:38Z","timestamp":1769506478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/3\/921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":98,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["jcm15030921"],"URL":"https:\/\/doi.org\/10.3390\/jcm15030921","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]}}}